Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (361-370 of 483) with videos related to

Pageof 49
Sort By:
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
NPJ Precision Oncology|April 9, 2024
Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapyMaxime W Lafarge, Enric Domingo, Korsuk Sirinukunwattana, et al.
Haematologica|October 19, 2010
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, Christina-Maria Hartog, Renato Bassan, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Thrombosis and Haemostasis|July 13, 2021
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-PaclitaxelJakob M Riedl, Esther Schwarzenbacher, Florian Moik, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Journal for Immunotherapy of Cancer|November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsTodd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Pageof 49

Showing results (361-370 of 483) with videos related to

Sort By:
Pageof 49
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
NPJ Precision Oncology|April 9, 2024
Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapyMaxime W Lafarge, Enric Domingo, Korsuk Sirinukunwattana, et al.
Haematologica|October 19, 2010
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, Christina-Maria Hartog, Renato Bassan, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Thrombosis and Haemostasis|July 13, 2021
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-PaclitaxelJakob M Riedl, Esther Schwarzenbacher, Florian Moik, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Journal for Immunotherapy of Cancer|November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsTodd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Pageof 49